- Home
- ROIV vs SUI Comparison
ROIV vs SUI Comparison
Compare ROIV & SUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | SUI |
|---|---|---|
| Founded | 2014 | 1975 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 15.5B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | ROIV | SUI |
|---|---|---|
| Price | $21.70 | $123.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $21.94 | ★ $138.33 |
| AVG Volume (30 Days) | ★ 6.7M | 606.2K |
| Earning Date | 11-10-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 3.40% |
| EPS Growth | N/A | ★ 324.78 |
| EPS | N/A | ★ 7.94 |
| Revenue | $20,329,000.00 | ★ $3,236,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $376.94 | $5.37 |
| P/E Ratio | ★ N/A | $15.39 |
| Revenue Growth | N/A | ★ 32.39 |
| 52 Week Low | $8.73 | $109.22 |
| 52 Week High | $22.45 | $137.77 |
Technical Indicators
Market Signals| Indicator | ROIV | SUI |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 41.50 |
| Support Level | $20.14 | $122.13 |
| Resistance Level | $21.48 | $125.45 |
| Average True Range (ATR) | 0.71 | 2.31 |
| MACD | 0.00 | -0.63 |
| Stochastic Oscillator | 65.96 | 20.68 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.